HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. - Wikidata - wikimedia - TriplyDB

HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin.

HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin.

http://www.wikidata.org/entity/Q43032582

about

Strategies to reduce hepatitis C virus recurrence after liver transplantation Diagnosis, management, and treatment of hepatitis C: an update Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review.Future treatment of patients with HCV cirrhosis.Management of recurrent hepatitis C following liver transplantation.Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients.Antiviral therapy in patients after treatment for hepatitis C-related hepatocellular carcinoma.Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.Treatment of patients with HCV related cirrhosis: many rewards with very few risks.IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS.Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients SASLT practice guidelines: management of hepatitis C virus infection.Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection.Direct-acting antiviral agents in patients with hepatitis C cirrhosis.Hepatitis B and C in liver transplantation: new strategies to combat the enemies.Role of liver biopsy in the era of direct-acting antivirals.Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality Evaluating Andrographolide as a Potent Inhibitor of NS3-4A Protease and Its Drug-Resistant Mutants Using In Silico Approaches High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention.Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis.Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients.Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment.Frequent coinfection with hepatitis among HIV-positive patients in Urumqi, China.Managing patients with hepatitis‑B-related or hepatitis‑C-related decompensated cirrhosis.Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology.Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forward.

P2860

Q22305418-C1A7E094-C8C7-48C0-9668-989A1A19842D Q29619682-90404496-8C8B-4E04-8ABD-81D9E139CE99 Q33406835-08CF4D83-85C9-4461-A3AC-304CEAB16259 Q34243993-64C84ED5-6DC6-4765-AA2D-6B1B3E0D1C96 Q34298333-83CC08F7-4CCC-437F-B308-B54C251985E5 Q34334776-AE09FE3B-3EA1-4821-9B0E-C078D3D161D2 Q34467312-02248F4E-BD8C-4865-8ED4-D28D34E16CE2 Q34725891-A5B062B2-53CE-47EB-810F-40B1F64C410C Q35226081-128C8063-3099-4D77-A30D-5F1F2113BC76 Q36142732-59A86DA3-DE48-4E7A-B5A0-952CD87D1499 Q36935025-1DCA9656-0573-430E-968B-AC8E9E17F5A0 Q36983527-A8DFA824-4EB0-4908-98BB-152DDA74CB51 Q37019765-F6B73DBA-86E5-4E65-B14D-7DA65C2AF5B9 Q37534731-0082C524-00C0-4AD4-9572-7633FE679FC6 Q37663921-49F3133E-6DE4-428E-B27F-668D923DA67D Q38067343-C9AFAC6C-2D76-4ED4-9F37-A337BEAFD32B Q38074087-645E420A-402F-4F01-BB24-244537F780A1 Q38198618-BADB8218-7C4F-49AD-AFD2-F86E9742C208 Q40902793-F563939F-F206-4882-9F7E-0E25CD7E5D95 Q41412067-48899E95-4A91-4674-80F7-740385F811AB Q42287249-F707D87A-F002-4C73-8598-433476492DF2 Q42581407-DCD71160-6028-4246-A1DF-E6B1541F2663 Q42987104-98D8E006-B791-4B0E-8758-0A247BA09A64 Q43000439-65EE072F-A008-499A-A3F4-0C8049DC6A9C Q43736700-ABF0FB07-B597-446D-9616-497845F25BB5 Q44074214-F5BAA3A0-6434-4C0A-82B2-9E7EF1FF7E1B Q45027152-819CE47E-A830-4154-83C0-0857F8F8576E Q45353010-9A41DB0B-0DDC-4DB3-91E8-E85AEE9BB1A2 Q45836877-8BB6D616-CF77-4585-960F-C54772633408

P2860

HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin.

http://www.wikidata.org/entity/Q43032582

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

HCV-related advanced fibrosis/ ...... rferon alpha-2a and ribavirin.

@en

HCV-related advanced fibrosis/ ...... rferon alpha-2a and ribavirin.

@nl

type

label

HCV-related advanced fibrosis/ ...... rferon alpha-2a and ribavirin.

@en

HCV-related advanced fibrosis/ ...... rferon alpha-2a and ribavirin.

@nl

prefLabel

HCV-related advanced fibrosis/ ...... rferon alpha-2a and ribavirin.

@en

HCV-related advanced fibrosis/ ...... rferon alpha-2a and ribavirin.

@nl

P1433

Q43032582-AA5A1895-C28F-4AD5-81EB-6124B117B880

P1476

Q43032582-5B222CCF-C4CD-4F45-9B7D-E5E39C9C30CF

P2093

Q43032582-34D2F161-0010-4F33-ACEF-C2FF4E4A7E6D

Q43032582-40F5952D-0E1F-46FC-A678-870F33BBA45B

Q43032582-78823113-B759-478E-B0D7-1CEB89B301F3

Q43032582-A06756D6-11F4-4B9A-92A7-76F553B0A28F

Q43032582-A589AEBB-495D-45A1-8984-830CFB595108

Q43032582-C7996D40-A9DD-4B59-9962-FA9F4CDF4AA4

Q43032582-E6BB6477-9722-4CFC-B6C0-B2405D46A2A8

Q43032582-E840924A-7272-40CA-A734-C24D9093A7B9

Q43032582-EC6E3EA0-3F47-472D-AA43-F4DED1F7A40C

Q43032582-F1FA476C-2C6B-44CD-855E-A8495759CF21

P2860

Q43032582-0CD69544-487D-4503-A721-9E9968DF6CA0

Q43032582-0EB4A2D0-1708-4064-A2E8-48C998D29FCD

Q43032582-11A7FDA8-49CE-419C-9CD8-1CEE5BE36697

Q43032582-19F1BDF9-8377-4C81-AD77-679080A6237C

Q43032582-22F85899-F07A-47AC-A942-6E8E7B72A53A

Q43032582-44A22D47-1CF8-40F7-ADA6-3CD19297EC50

Q43032582-7782ED30-EAF9-4948-A487-7F36EC3D27C3

Q43032582-89297457-81DF-42B7-B8CD-4AC586E155E0

Q43032582-A8D51C37-896D-4CB8-9372-5812A90EB780

Q43032582-AAC885BC-001C-4709-A640-5E6F88485F5D

P304

Q43032582-8FE6C2CD-C0A2-4FF1-B089-917FCCA0060E

P31

Q43032582-A5E2DEE9-C9FB-4294-883A-08FB8DA061E8

P356

Q43032582-A0308EFD-3AA3-4DC3-B0D0-BEB276F9D57E

P433

Q43032582-A9419523-B88B-4B52-AF42-9D59D533883E

P478

Q43032582-A29B19B0-6B4E-4E50-A877-9FDA30B37516

P577

Q43032582-81706337-FF10-41BA-BA6E-7B66C9A1653A

P698

Q43032582-2DFEDB60-3A0A-461B-A941-05468652AFF3

P356

J.1365-2893.2006.00753.X

P1433

Journal of Viral Hepatitis

P1476

HCV-related advanced fibrosis/ ...... rferon alpha-2a and ribavirin.

@en

P2093

Alicia Esteban

http://www.w3.org/2001/XMLSchema#string

Andreas Cerny

http://www.w3.org/2001/XMLSchema#string

Beat Helbling

http://www.w3.org/2001/XMLSchema#string

Beat Meyer-Wyss

http://www.w3.org/2001/XMLSchema#string

Beat Müllhaupt

http://www.w3.org/2001/XMLSchema#string

Eberhard L Renner

http://www.w3.org/2001/XMLSchema#string

Ivan Stamenic

http://www.w3.org/2001/XMLSchema#string

J Borovicka

http://www.w3.org/2001/XMLSchema#string

Jean-Jacques Gonvers

http://www.w3.org/2001/XMLSchema#string

Marina Knöpfli

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

Histological grading and staging of chronic hepatitis

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.

Side effects of therapy of hepatitis C and their management.

Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys

Renal insufficiency may partly explain chronic anemia in patients awaiting liver transplantation.

Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys.

Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function.

P304

762-769

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2893.2006.00753.X

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17052276

http://www.w3.org/2001/XMLSchema#string